LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
The firm recorded an accounting impairment in Q4 for excess manufacturing and inventory related to the scale-up during peak COVID-19 testing demand and the decision to pause commercialization of its Amira COVID-19 test.
Source: labpulse.com